We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · April 12, 2021

Safety of Alemtuzumab and Autologous HSCT Compared With Noninduction Therapies for MS

Neurology

 

Additional Info

Neurology
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
Neurology 2021 Mar 16;96(11)e1574-e1584, P Alping, J Burman, J Lycke, T Frisell, F Piehl

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading